Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative treatments for ophthalmic diseases. The company's lead product, KIO-301, is a molecular photoswitch designed to restore light perception and improve vision in patients suffering from inherited and age-related retinal degeneration, including conditions such as retinitis pigmentosa, choroideremia, and Stargardt disease. Kiora is also developing KIO-101, a next-generation non-steroidal, immuno-modulatory small molecule inhibitor targeting dihydroorotate dehydrogenase, aimed at minimizing off-target side effects while effectively managing immune responses. Additionally, Kiora is working on KIO-201, a modified form of hyaluronic acid intended to promote corneal wound healing. Through these products, Kiora Pharmaceuticals seeks to address significant unmet medical needs in the ophthalmic space.
Jade Therapeutics
Acquisition in 2016
Jade Therapeutics, Inc. specializes in the development of ophthalmic sustained-release drug delivery platforms aimed at enhancing corneal healing after disease or injury while also improving visual function and quality of life. The company’s innovative products utilize recombinant human growth hormone, a biologic known for its healing properties, to activate and recruit key cells involved in tissue repair. This approach not only facilitates the repair of corneal epithelial defects that have been resistant to traditional treatment but also promotes better patient adherence to therapy. By reducing the frequency of administration and the need for office visits, Jade Therapeutics aims to alleviate the burden of illness for patients. Established in 2011 and headquartered in Salt Lake City, Utah, Jade Therapeutics operates as a subsidiary of Eyegate Pharmaceuticals, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.